Dysregulation of the secretory pathway connects Alzheimer’s disease genetics to aggregate formation

Highlights

• Graph-based model links secretory-pathway dysregulation to amyloid aggregation

• Concerted patterns of repression converge on the core support network

• Key Alzheimer’s disease perturbations overlap with the core support network

Summary

Amyloid disorders such as Alzheimer’s disease (AD) involve the aggregation of secreted proteins. However, it is largely unclear how secretory-pathway proteins contribute to amyloid formation. We developed a systems biology framework integrating expression data with protein-protein interaction networks to estimate a tissue’s fitness for producing specific secreted proteins and analyzed the fitness of the secretory pathway of various brain regions and cell types for synthesizing the AD-associated amyloid precursor protein (APP). While key amyloidogenic pathway components were not differentially expressed in AD brains, we found Aβ deposition correlates with systemic down- and upregulation of the secretory-pathway components proximal to APP and amyloidogenic secretases, respectively, in AD. Our analyses suggest that perturbations from three AD risk loci cascade through the APP secretory-support network and into the endocytosis pathway, connecting amyloidogenesis to dysregulation of secretory-pathway components supporting APP and suggesting novel therapeutic targets for AD.

A record of this paper’s transparent peer review process is included in the supplemental information.